Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Andres Peleteiro Raindo"'
Refining risk prediction in pediatric acute lymphoblastic leukemia through DNA methylation profiling
Autor:
Adrián Mosquera Orgueira, Olga Krali, Carlos Pérez Míguez, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Manuel Fernández Sanmartín, Daniel Sinnet, Mats Heyman, Gudmar Lönnerholm, Ulrika Norén-Nyström, Kjeld Schmiegelow, Jessica Nordlund
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-13 (2024)
Abstract Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children, and despite considerable progress in treatment outcomes, relapses still pose significant risks of mortality and long-term complications. To address this challenge,
Externí odkaz:
https://doaj.org/article/524a99df0c2a49bea5b4ae1c671020b2
Autor:
Adrián Mosquera Orgueira, José Ángel Díaz Arias, Miguel Cid López, Andrés Peleteiro Raíndo, Beatriz Antelo Rodríguez, Carlos Aliste Santos, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, José Luis Bello López
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Thirty to forty percent of patients with Diffuse Large B-cell Lymphoma (DLBCL) have an adverse clinical evolution. The increased understanding of DLBCL biology has shed light on the clinical evolution of this pathology, leading to
Externí odkaz:
https://doaj.org/article/47def9812b5e4561b9a2ffba19e04710
Autor:
Adrián Mosquera Orgueira, Miguel Cid López, Andrés Peleteiro Raíndo, Aitor Abuín Blanco, Jose Ángel Díaz Arias, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Laura Bao Pérez, Roi Ferreiro Ferro, Carlos Aliste Santos, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Claudio Cerchione, Pablo Mozas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Follicular Lymphoma (FL) has a 10-year mortality rate of 20%, and this is mostly related to lymphoma progression and transformation to higher grades. In the era of personalized medicine it has become increasingly important to provide patients with an
Externí odkaz:
https://doaj.org/article/946e64e6f3364a31836120ae590b10a7
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Roi Ferreiro Ferro, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Paula Melero Valentín, Marta Sonia González Pérez, Claudio Cerchione, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0247093 (2021)
BackgroundFLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Cu
Externí odkaz:
https://doaj.org/article/cbe01aa7d0234032abc58f5a46490841
Autor:
Adrian Mosquera-Orgueira, Jose Angel Diaz Arias, Rocio Serrano Martin, Victor Portela Piñeiro, Miguel Cid Lopez, Andres Peleteiro Raindo, Laura Bao Perez, Marta Sonia Gonzalez Perez, Manuel Mateo Perez Encinas, Maximo Francisco Fraga Rodriguez, Juan Carlos Vallejo Llamas, Jose Luis Bello Lopez
Publikováno v:
HemaSphere, Vol 7, p e2637897 (2023)
Externí odkaz:
https://doaj.org/article/fd9332847a1e418ba40e929405d28bee
Autor:
Adrian Mosquera-Orgueira, Jose Angel Diaz Arias, Rocio Serrano Martin, Victor Portela Piñeiro, Andres Peleteiro Raindo, Miguel Cid Lopez, Laura Bao Perez, Marta Sonia Gonzalez Perez, Manuel Mateo Perez Encinas, Maximo Francisco Fraga Rodriguez, Juan Carlos Vallejo Llamas, Jose Luis Bello Lopez
Publikováno v:
HemaSphere, Vol 7, p e681104f (2023)
Externí odkaz:
https://doaj.org/article/57236ee22ecb4d8ea3d02857c3f057bc
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/5b644d52caf6407c83da3785ab40f5bd
Autor:
Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Rocio Serrano Martín, Victor Portela Piñeiro, Miguel Cid López, Andrés Peleteiro Raíndo, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Juan Carlos Vallejo Llamas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short su
Externí odkaz:
https://doaj.org/article/617f5691a8e74047b11c6b9eeaa33179
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or int
Externí odkaz:
https://doaj.org/article/5aede6c8b7c54ba38df284fa7e1db4fd
Autor:
Marina Gómez-Llobell, Andrés Peleteiro Raíndo, Jose Climent Medina, Ignacio Gómez Centurión, Adrián Mosquera Orgueira
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundExperience with immune checkpoint inhibitors (ICIs) in the treatment of acute myeloid leukemia (AML) is still limited and based on early clinical trials, with no reported randomized clinical data. In this study, we reviewed the available ev
Externí odkaz:
https://doaj.org/article/07cb54b021d04747aa020b37a948fd52